α-Bisabolol Mitigates Colon Inflammation by Stimulating Colon PPAR-γ Transcription Factor: In Vivo and In Vitro Study

Figure 6

Effect of bisabolol pretreatment on LPS-stimulated RAW264.7 macrophage viability, proinflammatory cytokine response, PPAR-γ, PPAR-α, PPAR-β, and protein expression. Bisabolol treatment did not affect RAW264.7 cell viability at 24 h and 48 h (a, b). RAW cells were pretreated with bisabolol for 6 hr, subsequently stimulated with LPS for 24 hr. Bisabolol pretreatment significantly reduced proinflammatory cytokine response at protein (IL-6 (c), IL-1β (d), and TNF-α (e)) and mRNA levels (IL-6 (f), IL-1β (g), and TNF-α (h)). Bisabolol pretreatment significantly increased PPAR-γ protein expression (i),\ but did not affect PPAR-α (j) and PPAR-β (k) protein expression. Bisabolol pretreatment significantly prevented the increase in the phosphorylation of pNF-κB p65 protein (l). The density of immunoblots was normalized to GAPDH. Five () different experiments were run for Western blot and mRNA measurements. The data expressed as . , , and . ns: not significant.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)